Oral acyclovir and recurrent genital herpes during late pregnancy.
OBJECTIVE
To assess plasma acyclovir levels in pregnant women given oral acyclovir during late gestation and to determine the role and effect of oral acyclovir on asymptomatic shedding of virus in cases of recurrent genital herpes.


METHODS
Five pregnant women with proven genital herpes isolate (herpes simplex virus [HSV] 2) after 37 weeks' gestation were studied. Oral acyclovir was administered every 8 hours at dosages of 300, 400, and 300 mg in two subjects, and 200 mg five times daily in the other three until delivery. Plasma acyclovir peak and trough levels were determined. Viral cultures were obtained from both the mothers and neonates at delivery.


RESULTS
There was no difference in acyclovir plasma levels among the patients. Furthermore, acyclovir levels were comparable to those of nonpregnant adults. The drug failed to suppress asymptomatic shedding of virus and transmission of HSV 2 to the neonate in one of five of the patients.


CONCLUSIONS
Our study suggests that asymptomatic shedding of virus is not prevented by use of oral acyclovir during late gestation in proven recurrent genital herpes even though plasma acyclovir levels were within the normal range.
Service de Néonatologie, Hospital University of Strasbourg, France.
J
J
Haddad
B
B
Langer
D
D
Astruc
J
J
Messer
F
F
Lokiec
D000212:Acyclovir / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000284:Administration, Oral; D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000382:microbiology; D011263:Pregnancy Trimester, Third; D018139:Simplexvirus / Q000302:isolation & purification
D000212:Acyclovir